Kornimate/medical-research-clean huggingface dataset:
rtms for chr based on personalized targets using magnetoencephalography

Conditions: Clinical High-risk Syndrome of Psychosis

Summary: this study is an before-after study in the same subject, which enrolled 26 individuals with high-risk psychiatric syndrome (chr). the target of subjects intervention relies on the results of magnetoencephalography localization. the medication and dosage remain unchanged during the intervention period or not yet taking antipsychotic medication. the investigators assume that the intervention targets for each chr subject are individualized.

this study is divided into two parts: 1. target determination. firstly, meg data of the subject's resting and task states are collected, and a precise localization model using magnetoencephalography is applied to locate the precise location of the subject's abnormal signals in the brain, which is then used as the intervention target. based on the subject's tolerance for single day intervention, the appropriate number of targets is generally 2-4. the upper limit of targets is 4. 2. rtms individualized intervention. application of rtms for 1hz low-frequency intervention, with intervention parameters of 1400 sessions, 100% exercise threshold, and a total of 23 minutes per session. after each target intervention, rest for half an hour to one hour. the pseudo stimulation intervention lasted for 10 days in the first and second weeks, and the scale was evaluated after the end of the pseudo stimulation. after resting for 2 weeks, enter the 3-4 weeks of real stimulation, with 5 days of intervention per week for a total of 10 days. 2-4 targets per day, 23 minutes per target, with 30-60 minutes between interventions for each target. after the fourth week, evaluate the scale. follow up evaluations will be conducted on the 7th, 14th, 30th, 60th, and 90th day after intervention. by analyzing and evaluating data, explore individualized treatment plans for chr in clinical practice.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of clinical high-risk syndrome for psychosis * must be able to right-handed * primary school education or above * understand and sign a written informed consent form (jointly signed by the guardian and the participant if under 18 years old) exclusion criteria: * major physical illnesses (organic lesions such as sensory and motor disorders, neurological disorders, and traumatic brain injury) * taboo symptoms for rtms treatment (such as intracranial metal implants) * metal (including orthodontic treatment, dental implants) and tattoos inside the body * claustrophobia

Keywords: clinical high-risk syndrome of psychosis meg rtms individualized targets
a randomized trial of ostomy closure techniques

Conditions: Wound Infection

Summary: stoma closure has been associated with a high rate of surgical site infection (ssi). the rate for ssi following stoma closure has been noted to be 7-41%; a rate that is higher than expected for a clean-contaminated operative classification. the ideal stoma site closure technique is still debated in the current literature. the aim of this study was to compare the rate of ssi following two different stoma closure techniques, primary closure versus a skin approximating purse string closure, in a multi-center randomized controlled trial. the investigators hypothesize that purse string closure technique will have a lower rate of ssi than primary closure technique.

the investigators will randomize ileostomy takedown patients to either a primary closure or purse string closure technique intraoperatively. surgeons at both the university of minnesota and the chuv hospital in switzerland will participate in the this study.

Eligibility criteria:
inclusion criteria: subjects eligible are those with either a colostomy or ileostomy (end or loop) who are deemed by their surgeon to be appropriate candidates for ostomy closure. there will be no limitations based upon initial indication for formation of the ostomy. indications for initial ostomy formation for fecal diversion can include: infection (e.g. diverticulitis) and protection of an anastomosis. (following resection for inflammatory bowel disease, benign diseases, or cancer) exclusion criteria: subjects will be excluded from the study if: 1. the stoma site is left open to heal by secondary intention due to gross contamination (surgeon discretion) 2. the stoma site is re-used (i.e. the same stoma site used for the formation of a new ostomy) 3. a new stoma is created at a different site.

Keywords: surgical stomas ileostomy surgical site infection
clinical course of cirrhotic patients with portal vein thrombosis treated with tips

Conditions: Portal Vein Thrombosis

Summary: portal vein thrombosis (pvt) is defined as an obstruction of the portal vein. the prevalence of pvt is 10-25% and incidence is about 16% in cirrhotic patients. pvt leads to increased intrahepatic resistance, decreased portal velocities, splanchnic vasodilatation, and stagnant flow. portal vein recanalization (pvr) with transjugular intrahepatic portosystemic shunt (tips) is aimed at restoring main portal vein (pv) flow in chronic pvt. in this study, we will review the safety and outcomes of this approach.

portal vein thrombosis (pvt) is a fairly common complication of liver cirrhosis. importantly, occlusive pvt might influence the prognosis of patients with cirrhosis. transjugular intrahepatic portosystemic shunt (tips) has been reported to be an effective treatment of pvt in cirrhosis, with the advantage of avoiding the risk of bleeding linked to anticoagulation. in this study, we will evaluate the outcome of tips for pvt in patients with and without cirrhosis and determinate survival.

Eligibility criteria:
inclusion criteria: * written informed consent * liver cirrosis or non-cirrhotic patients * portal vein thrombosis (degree of vessel obstruction \> 50%) exclusion criteria: * active variceal bleeding * prior history of tips placement or shunt surgery * concomitant renal insufficiency * severe cardiopulmonary diseases * uncontrolled sepsis serious medical conditions which may reduce the life expectancy * contraindications for tips
bone toxicity following pelvic radiotherapy

Conditions: Gynecologic Cancer; Radiotherapy Side Effect; Fracture

Summary: a randomised controlled clinical feasibility trial to determine the feasibility and acceptability of a "musculoskeletal health package (mhp)" intervention in women undergoing pelvic radiotherapy for gynaecological malignancies and inform power calculations for a definitive trial.


Eligibility criteria:
inclusion criteria: * age over 18 years * histologically confirmed uterine or cervix cancer * patients undergoing potentially curative/adjuvant radiotherapy * ability to give informed consent to participate exclusion criteria: * age less than 18 years or greater than 85 years * patients with pre-existing bone conditions such as: osteoporosis treated with bisphosphonates in the previous 5 years/fibrous dysplasia/osteogenesis imperfecta or other metabolic bone condition * inability to give informed consent to participate * home address outside greater manchester * contraindication or intolerance of magnetic resonance scanning
the role of short-course ceftriaxone therapy in the treatment of severe nontyphoidal salmonella enterocolitis

Conditions: Diarrhea

Summary: the purpose of the investigators study is to evaluate if short-course of ceftriaxone therapy could shorten the clinical courses of severe nontyphoidal salmonella enterocolitis in children and the excretion of salmonella in feces.

nontyphoidal salmonellae (nts) is one of the most important pathogens of gastroenteritis in humans. although most nontyphoidal salmonella infections result in self-limited gastroenteritis, invasive infections such as bacteremia, meningitis or extraintestinal infection could also occur. antimicrobial therapy is not recommended for routine treatment of nontyphoidal salmonellosis and effective antibiotic treatment is essential if nts infection spreads beyond the intestine such as bacteremia, meningitis or osteomyelitis. although some reports revealed that antimicrobial therapy may be beneficial for shortening the clinical courses of severe nts enterocolitis, most of them were based on clinical observations, not based on the results of objective examinations. thus, the use of antibiotics in the treatment of patients with severe nts gastroenteritis is still controversial in clinical practice. as a third generation cephalosporin, ceftriaxone has a higher concentration than conventional antibiotics such as ampicillin and trimethoprim-sulfamethoxazole in the intestinal mucosa and gallbladder. besides, ceftriaxone maintains relatively lower resistance rate in salmonella than those of other conventional antibiotics. so the purpose of our study is to evaluate if short-course of ceftriaxone therapy could shorten the clinical courses of severe nts enterocolitis in children and the excretion of salmonella in feces. the investigators think that the study may be helpful for clinicians in the treatment of severe nts enterocolitis in children, especially on the judgments of the choices and the treatment cures of antibiotics.

Eligibility criteria:
inclusion criteria: * children with suspected severe salmonella enterocolitis * defined as those with a high fever (core body temperature ≥ 38.5℃) persisting for longer than 48 hours * diarrhea with mucous and bloody-tinged stool. exclusion criteria: * children with a toxic appearance, severe vomiting and abdominal distension * suggestive of sepsis or toxic megacolon, those with an increased risk of invasive nts diseases * immunosuppressive illnesses * had taken antibiotics during the 7 days before the visit will be excluded.

Keywords: nontyphoidal salmonellae enterocolitis ceftriaxone
rehabilitation of memory symptoms after brain concussion

Conditions: Concussion, Brain; Mild Traumatic Brain Injury

Summary: persistent memory symptoms after concussion are common, and likely perpetuated by unhelpful illness beliefs and coping behaviors. results from a pilot study suggested that traditional cognitive rehabilitation and a novel cognitive-behavioral therapy (cbt) protocol were both associated with improvements in subjective memory functioning. the present study will more definitively compare the effectiveness of these interventions for improving subjective memory functioning after concussion.

the primary research aims of this study are to determine whether cognitive behavioral therapy (cbt) and cognitive compensatory strategy training (ccst) improves subjective memory functioning compared to usual care, and to compare the effectiveness of cbt and ccst. this study is a multisite three-armed randomized control trial (rct) that will randomize adults with persistent memory symptoms following concussion to cbt, ccst, or a covert waitlist condition (2:2:1). participants will be blinded to the other arms of the study and the study hypotheses.

Eligibility criteria:
inclusion criteria: 1. age 18-59 2. concussion diagnosis confirmed with structured interview based on american congress of rehabilitation medicine diagnostic criteria 3. concussion occurred between 6 and 36 months before enrollment 4. ongoing memory concerns 5. fluent in english 6. stable access to a computer, tablet, or smartphone with internet capability exclusion criteria: 1. fail performance validity testing 2. comorbid psychiatric or neurological disorder or is taking a medication that could fully account for their memory symptoms

Keywords: functional cognitive disorder
long--term outcome analysis of fracture--related infections

Conditions: Fracture-associated Infection (FAI)

Summary: this retrospective analysis of medical records is to identify risk factors for treatment failures in fracture-associated infections (fai) at the university hospital basel.


Eligibility criteria:
inclusion criteria: * patients with fai exclusion criteria: * documented denial of consent

Keywords: prosthesis infection
second toe length and hallux valgus: greek vs. egyptian foot

Conditions: Hallux Valgus

Summary: a total of 150 patients aged 60-80 years with existing foot radiographs will be included in the study. radiographic evaluations will include measurements of the hallux valgus angle, first intermetatarsal angle, and the metatarsal and phalanx lengths of the first and second toes. the ratio of the second toe phalanx length to the first toe phalanx length will be calculated and recorded. the relationship between the hallux valgus angle, toe lengths, and their ratios will be analyzed using statistical methods.


Eligibility criteria:
inclusion criteria: * age between 60-80 years * presence of foot radiographs suitable for measurement * no history of prior foot surgery exclusion criteria: * history of foot trauma or fractures * previous foot or toe surgery * presence of congenital foot deformities * neurological or rheumatologic conditions affecting foot structure * severe osteoarthritis or other degenerative foot diseases visible on radiographs
a safety evaluation trial of tev-48125 self-administered in migraine patients

Conditions: Migraine

Summary: this trial assesses the safety of tev-48125 when subcutaneously self-administered in japanese migraine patients using an autoinjector (ai) at home. each subject will subcutaneously self-administer tev 48125 at 225 mg/1.5 ml (150 mg/ml) once monthly for a total of 2 doses. the first dose will be self-administered at the trial site under the supervision of the investigator and the second dose will be self-administered at home.


Eligibility criteria:
inclusion criteria: * patient has a history of migraine (according to the ichd-3 criteria) diagnosis for ≥12 months prior to giving informed consent. * patient fulfills any of the migraine criteria(according to the ichd-3 criteria) on ≥4 days in baseline information collected during the 28-day screening period exclusion criteria: * history of hypersensitivity reactions to injected proteins, including monoclonal antibodies * prior exposure to a monoclonal antibody targeting (cgrp) pathway meeting the following conditions: * less than 5 months has passed since the final administration of amg334, ald304, or ly2951742. * less than 1 year has passed since the final administration of tev-48125
an observational study of patients with lysosomal acid lipase deficiency/cholesteryl ester storage disease phenotype

Conditions: Cholesterol Ester Storage Disease(CESD); Lysosomal Acid Lipase Deficiency

Summary: this is a natural history study to characterize key aspects of the clinical course of late onset lysosomal acid lipase (lal) deficiency/ cholesteryl ester storage disease (cesd).

the objective of this study is to characterize key aspects of the clinical presentation, disease phenotype and progression of patients with late onset lysosomal acid lipase (lal) deficiency/ cholesteryl ester storage disease (cesd) including, but not limited to, age of presentation, onset of hepatomegaly, progression over time of liver function, and stability of lipid abnormalities.

Eligibility criteria:
inclusion criteria: * patients with late onset lal deficiency/ cholesteryl ester storage disease (cesd) who are 5 years of age or older and have required data points in their medical record exclusion criteria: * required data points for inclusion are not available

Keywords: lysosomal storage disease late onset lysosomal acid lipase (lal) deficiency acid cholesteryl ester hydrolase deficiency, type 2 acid lipase disease cholesterol ester hydrolase deficiency lal deficiency lipa deficiency wolman disease
effects of tavns on fibromyalgia pain

Conditions: Fibromyalgia, Pain

Summary: transauricular vagus nerve stimulation (tavns) is a newer delivery system, using a non-invasive stimulation device placed at the ear's concha. tavns is a portable, safe, and low-cost intervention, and according to some studies, tavns may influence nociception and pain perception, which can lead to potential applications for various painful illnesses, including fibromyalgia (fm). this trial aims to investigate the clinical effects of tavns on pain control in fm subjects.


Eligibility criteria:
inclusion criteria: 1. older than 18 years old. 2. diagnosis of fm pain according to the american college of rheumatology (acr) 2010 criteria (existing pain for more than six months with an average of at least 3 on a 0-10 vas scale). 3. must have the ability to feel sensation by von-frey fiber on the forearm. 4. able to provide informed consent to participate in the study. exclusion criteria: 1. subjects who have unstable medical conditions (e.g., uncontrolled diabetes, uncompensated cardiac issues, heart failure, or chronic obstructive pulmonary disease) or who have functional deficits, as self-reported. 2. history of substance abuse within the past six months as self-reported (if the subject reports a history of substance abuse, we will confirm using the diagnostic and statistical manual of mental disorders (dsm-v) criteria). 3. presence of implanted cranial electronic medical devices (e.g., cochlear implants). 4. pregnancy (as the safety of tavns in the pregnant population (and children) has not been assessed (though the risk is non-significant), we will exclude pregnant women (and children). women of child-bearing potential will be required to take a urine pregnancy test during the screening process and every two weeks of stimulation).
a study to assess the efficacy and safety of namilumab in participants with chronic pulmonary sarcoidosis

Conditions: Sarcoidosis, Pulmonary

Summary: this is a randomized, double-blind, placebo-controlled study with an open-label extension (ole).

this is a randomized, double-blind, placebo-controlled study with an ole. participants will be randomized to receive namilumab or placebo in the 26-week double-blind treatment period of the study. namilumab, or placebo, will be administered subcutaneously (sc) every 4 weeks through week 22 after the initial dosing period. all participants who complete the 26-week double-blind treatment period, may be eligible to participate in the 28-week ole. further details are in the protocol.

Eligibility criteria:
inclusion criteria : * male or female age ≥18 years * able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form * greater than or equal to 6-month history of documented sarcoidosis including histological confirmation in the subject's medical records * evidence of sarcoidosis as indicated by: a) hrct consistent with pulmonary sarcoidosis and; b) medical research council dyspnea scale \>1 (i.e., grade 2 or more) and; c) one or more of the following is present: i) screening fdg-pet scan consistent with active pulmonary sarcoidosis and suvmax ≥ 3; ii) recent history of worsening sarcoidosis; iii) recent history that tapering ocs and/or ists resulted in an increase of pulmonary disease * body mass index (bmi) ≤ 40 kg/m2 at screening * vaccinations for covid-19 with completion of the primary series at least 2 weeks prior to randomization exclusion criteria * hospitalized for any respiratory illness ≤ 30 days prior to or during screening * greater than or equal to 20% fibrosis as indicated on hrct-scan assessed by central read prior to randomization * hemoglobin ≤ 9.5 g/dl * participation in another interventional clinical trial (ip/device) within 6 months prior to screening, during screening and throughout the duration of the study * ecg abnormalities that warrant further clinical investigation or management at screening * systolic blood pressure (sbp) \ 180mm hg; diastolic blood pressure (dbp) \ 110 mm hg at screening * has documented laboratory-confirmed sars-cov-2 infection with pulmonary involvement or signs/symptoms of long covid as determined by approved testing ≤ 6 months prior to randomization * other significant pulmonary disease or conditions that prevent subject from performing acceptable spirometry * females who are pregnant or breastfeeding or intend to be during the course of the study * any other acute or chronic medical condition, psychiatric condition, or laboratory abnormality, that in the judgment of the investigator or sponsor, may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results, and would make the participant inappropriate for entry into this study * subjects who are treatment naive other protocol-defined inclusion/exclusion criteria apply.
emphasizing the personal versus the social in educational interventions for decreasing vaccine hesitancy

Conditions: Vaccine Hesitancy; Communication

Summary: this experimental study aims to investigate the effect of different types of educational interventions on overcoming coronavirus disease 2019 (covid-19) vaccine hesitancy among the higher school of economics (hse) bachelor students in russia.

the researchers aim to investigate the effectiveness of three types of educational interventions on overcoming covid-19 vaccine hesitancy among the hse bachelor students. the study design implies the comparison of three types of educational interventions which differ in the message that they deliver to the participants: the personal, the social, and a combination of the two. the effects of these interventions will be compared to the control group with no intervention. participants in these three experimental groups will receive a link to an educational video about the benefits and costs of vaccination against covid-19. the videos for the three groups will contain information about vaccination, but each of them will have a different focus. the participants will be hired on a voluntary basis. all the participants will sign the informed consent form, and the measures will be taken to ensure that their personal data will be protected.

Eligibility criteria:
inclusion criteria: * hse bachelor students from 18 to 25 years old, who agreed to participate in the study. exclusion criteria: * students who have got vaccinated already.

Keywords: vaccine hesitancy education covid-19 vaccine